跳至主要内容
临床试验/CTRI/2024/06/068990
CTRI/2024/06/068990尚未招募不适用

A cross-sectional analysis to assess the safety and Utilization of dydrogesterone in Patients with bad obstetRIc hiStory or habitual abortion in rEal world outpatients of India

Torrent Pharmaceuticals Ltd1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2024年6月26日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
2,000
试验地点
1
主要终点
Ongoing pregnancy rate (fetal viability confirmed with ultrasound)

研究概览

简要总结

  • This study is planned to evaluate the safety and effectiveness of dydrogesterone in Indian patients with bad obstetric history.
  • Study design**:**Post Approval Observational Studies (PAOS).
  • Duration of Observation**:**12 weeks (At least)
  • Study drug and dose: Dydrogesterone 10 mg

研究设计

研究类型
Observational

入排标准

年龄范围
20.00 Year(s) 至 99.00 Year(s)(—)
性别
Female

入选标准

  • Pregnant women up to 12 weeks of gestation
  • Women with a history of miscarriage with suspect luteal phase insufficiency
  • Patients willing for follow-up at scheduled visit as per protocol at same center.

排除标准

  • Known hypersensitivity or contraindication to study drug
  • Heavy vaginal bleeding requiring surgical intervention.
  • Any uterine anomalies.
  • Any associated medical and surgical illness.

结局指标

主要结局

Ongoing pregnancy rate (fetal viability confirmed with ultrasound)

时间窗: At 12 weeks

次要结局

  • Patient acceptability to treatment(At 4 weeks)
  • Safety assessment for Common Adverse events(At 4 weeks)

研究者

发起方
Torrent Pharmaceuticals Ltd
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Krupa Shah

Ayuh Fertility Centre

研究点 (1)

Loading locations...

相似试验